Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on March 30, 2017, regarding events occurring on March 24, 2017. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for cancer and pathological fibrosis.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel matters rather than financial performance data.
Material Changes
- Change in Certifying Accountant: The Audit Committee approved the immediate dismissal of BDO USA, LLP as the independent registered public accounting firm. KPMG LLP was previously engaged for the fiscal year ending December 31, 2017.
- Audit History: BDO's reports for fiscal years 2015 and 2016 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements or reportable events between the company and BDO regarding accounting principles or audit scope.
- Executive Compensation Goals: The Board approved 2017 corporate performance goals tied to cash bonuses for executive officers (William S. Marshall, Jason A. Leverone, Adam S. Levy, and Paul D. Rubin). Target bonus percentages range from 35% to 50% of base salary.
Guidance, Outlook, and Risks
The filing outlines specific corporate goals for 2017 that will determine executive compensation, including:
- Defining a development and registration path for MRG-106 (cancer treatment) and expanding its indications.
- Clinical advancement of MRG-201 (pathological fibrosis treatment).
- Development of the pre-clinical product candidate pipeline.
- Finance and business development objectives, including collaboration targets.
No specific financial guidance or risk factors beyond standard operational goals were disclosed in this document.
Investor Verification Checklist
- Verify the transition timeline and scope of work between BDO USA, LLP and KPMG LLP.
- Confirm the specific metrics used to measure the 2017 corporate goals for MRG-106 and MRG-201.
- Review the employment agreements for executive officers to understand the conditions for bonus payout.
- Check subsequent filings for the first financial statements audited by KPMG.